☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
US
ARTHEx Biotech Secures the US FDA’s Rare Pediatric Designation (RPD) to ATX-01 for Treating Myotonic Dystrophy Type 1 (DM1)
November 7, 2024
Shorla Oncology Reports the US FDA’s Expanded Approval of Jylamvo for Pediatric Indications
October 30, 2024
GSK to Acquire Chimagen Biosciences’ CMG1A46, Expanding its Immunology Pipeline
October 30, 2024
New Drug Designations - September 2024
October 29, 2024
Kind Pharmaceutical’s AND017 Gains the US FDA’s Orphan Drug Designation to Treat SCD
October 29, 2024
Modalis Therapeutics’ MDL-101 Gains the US FDA’s Orphan Drug Designation to Treat Congenital Muscular Dystrophy Type 1A (LAMA2-CMD...
October 28, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.